UCLA Mesothelioma Research Program to Sponsor First International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma
The UCLA Mesothelioma Research Program is sponsoring the First International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma. This unique symposium will take place Saturday, May 21 at the Sheraton Hotel in Santa Monica, Calif.
The course will be led by Dr. Robert Cameron, M.D., FACS, Director of the Mesothelioma Research Program at the David Geffen School of Medicine at ULCA, Chief of Thoracic Surgery at the West Los Angeles Veterans’ Administration Medical Center, and long-time advocate for lung-sparing surgery.
The course’s international faculty includes Dr. Tom Treasure, M.D., and Dr. David A. Walker, M.D., who will discuss the recent results of the Mesothelioma and Radical Surgery (MARS) Trial conducted in the U.K. The seminar wil also feature experts in the areas of surgery, radiation, chemotherapy and pulmonary medicine and was primarily designed for physicians.
Malignant pleural mesothelioma ia a cancer of the lining of the lungs typically caused by exposure to asbestos. On average, approximately 2,500 new cases are diagnosed each year in the U.S. and 43,000 cases are diagnosed worldwide.
There are a number of different treatment techniques for mesothelioma, typically involving chemotherapy, radiation therapy and surgery. There are, however, different schools of thought when it comes to these treatments. For example, some physcians prefer a minimally invasive technique, others prefer to be more aggressive when removing tumors.
You can learn more about mesothelioma treatment here.
